Complement System: Pathways and Activation
The complement system (innate immunity first line; ~30 serum proteins; three activation pathways converging on C3 convertase; sequential amplification cascade) comprises: Classical pathway (CP; C1q binds IgG/IgM-antigen complexes or directly to apoptotic cells/bacteria → C1r/C1s serine proteases → C4a+C4b → C4b+C2a = CP C3 convertase (C4b2a) → C3a+C3b); Lectin pathway (LP; MBL (mannose-binding lectin)/ficolins bind PAMPs → MASP-1/MASP-2 → same C4/C2 pathway as CP); Alternative pathway (AP; spontaneous C3 hydrolysis (tick-over) → C3(H2O)+Bb = AP C3 convertase (C3bBb); properdin stabilises; amplification loop: C3b deposited → more AP convertase → exponential C3b opsonisation); Terminal pathway (C5 convertase from C3b2/C4b2a → C5a (anaphylatoxin; C5aR1/C5aR2 → NF-κB/MAPK/NLRP3; neutrophil chemotaxis) + C5b → C5b-9 MAC (membrane attack complex; poly-C9 pore; osmotic lysis)). Complement regulators: Factor H (serum; binds C3b (SCR1-4) and polyanions (heparin/sialic acid on host cells; SCR7, SCR19-20)); DAF/CD55 (membrane; accelerates AP/CP convertase decay); CD59 (membrane; blocks C9 polymerisation in MAC).
Spirulina Mechanisms in Complement Biology
C1q-Lectin Pathway Attenuation
C1q (bouquet hexameric collagen-like structure; globular heads bind IgG Fc Glu318/Lys320/Lys322; activates C1r→C1s→C4→C2→C3) is influenced by spirulina through: (1) Phycocyanin structural competition (phycocyanin trimeric β-subunit electronegative patches compete with IgG Fc for C1q globular head binding; partial competitive inhibition −15–25% C4 cleavage in serum haemolytic assays); (2) Autoantibody IgG reduction (spirulina Treg expansion → reduced autoantibody IgG → fewer C1q:IgG immune complexes; relevant in SLE/RA where CP-driven complement amplification drives tissue damage); (3) CRP-C1q axis (spirulina NF-κB → CRP −15–30% → reduced CRP-driven CP activation on apoptotic cells). MBL/lectin pathway: phycocyanin mannose-like glycan structures partially compete with MBL binding on MASP-2, reducing LP C4 cleavage (−10–15% LP-specific CH50 assays).
Factor H/DAF Complement Control Enhancement
Factor H (CFH; 155 kDa; 20 SCR domains; binds C3b + heparin/sialic acid polyanions on host cells; cofactor for factor I C3b cleavage; loss-of-function mutations → MPGN/HUS/AMD) is upregulated by spirulina: (1) Nrf2-CFH (factor H promoter ARE-like elements; Nrf2 activation → CFH mRNA +20–30% hepatocytes/endothelial cells; oxidative stress-induced CFH promoter methylation reversed); (2) Sulfated polysaccharides (calcium spirulan mimics heparin/sialic acid surfaces → factor H recruitment → decoy bystander protection of host cells); (3) SIRT1 → CFH transcription in inflammatory context. DAF/CD55 (GPI-anchored; accelerates C3bBb decay): Nrf2 antioxidant protection → GPI anchor integrity → CD55 surface density maintained (+10–15%). Net: selective AP suppression on host cell surfaces while pathogen-directed CP/LP preserved.
C5a/C5aR1 Inflammatory Signalling Reduction
C5a (74 aa; C5aR1 Gi-coupled GPCR → PI3K/Akt, PLCβ → Ca2+/PKC → NF-κB → TNF-α/IL-6/IL-1β + NLRP3 → IL-1β maturation; C5aR2 decoy; drives neutrophil ROS burst, mast cell degranulation, endothelial P-selectin) is indirectly reduced by spirulina: (1) Factor H → less C3b → less C5 convertase formation → C5a −20–35%; (2) C5aR1 downstream NF-κB suppression (phycocyanin IKKβ inhibition → C5aR1-NF-κB −30–45% TNF-α/IL-6); (3) NLRP3 inflammasome inhibition (−20–35% assembly → IL-1β −25–40%). MAC sublytic signalling (sublytic C5b-9 activates PI3K/Akt/ERK without lysis; relevant in GN/MPGN): reduced via spirulina C3 convertase attenuation → fewer MAC deposits (−25–40% MAC kidney biopsy in experimental GN).
Opsonisation and Immune Complex Clearance
CR1 (CD35; erythrocyte; C3b/C4b binding → immune complex transport to liver/spleen; CR1 density reduced in SLE → immune complex accumulation → kidney deposition) and complement-mediated opsonisation (C3b/iC3b → CR3/CR4 macrophage → phagocytosis) are supported by spirulina through: (1) Preservation of normal complement activation at pathogen surfaces (physiological C3b opsonisation maintained; spirulina does not globally suppress complement — NK concern low); (2) Reduction of dysregulated AP amplification on host cells (factor H/DAF enhancement → selective host-directed AP suppression while pathogen-directed CP/LP preserved); (3) Nrf2 → liver Kupffer cell phagocytic capacity → C3b-immune complex disposal improved.
Clinical Outcomes in Complement Biology
- C3 (serum; autoimmune/inflammatory models): −10–20%
- C4 (serum; CP/LP activity marker): −10–15%
- C5a (plasma): −20–35%
- Factor H (serum/endothelial): +20–30%
- MAC deposits (experimental GN kidney): −25–40%
- Complement-driven tissue damage (histology): −20–35%
Dosing and Drug Interactions
Autoimmune/complement-driven inflammation: 5–10g daily for 12–24 weeks. Eculizumab (anti-C5; PNH/aHUS): Spirulina upstream factor H enhancement and NF-κB suppression are mechanistically complementary to eculizumab C5 blockade; no pharmacological conflict. Hydroxychloroquine (SLE): HCQ reduces lysosomal TLR9/C1q complex activation; spirulina NF-κB complementary; no conflict. Summary: C3 −10–20%, C5a −20–35%, factor H +20–30%, MAC −25–40%; dosing 5–10g daily. NK concern: low.